PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...

Session: Poster and Exhibition Hall Reception Poster Title:PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS ...

Eight abstracts related to MIPLYFFA have been accepted for poster presentation, including one selected for oral presentation by Dr. Eugen Mengel, discussing a significant clinical trial's efficacy ...

Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO NANTES, France - ...

Divide your poster presentation clearly into introduction, objective/hypothesis, methods, results, conclusion/discussion, and acknowledgement sections Do not include your abstract on the poster Make ...

Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposium Eight abstracts discussing data and clinical experience associated with MIPLYFFA accepted for poster ...

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a ...

This latest research builds upon the growing body of evidence demonstrating the unique impact of Brainomix's AI-powered software to expand access to life-changing stroke treatments across ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

WARNING: SEVERE HYPERSENSITIVITY REACTIONS Hypersensitivity Reactions Including Anaphylaxis Patients treated with Lamzede have experienced hypersensitivity reactions, including anaphylaxis.